Holen Sie sich die Stockscreener-App
2.747
4.62%
-0.133
Alto Neuroscience Inc Aktie (ANRO) Neueste Nachrichten
What analysts say about Alto Neuroscience Inc. stockBreakneck growth rates - Jammu Links News
Biotech Bargain Or Bust? Alto Neuroscience Faces Trial Test - Finimize
What makes Alto Neuroscience Inc. stock price move sharplyROI Focused Stock Calls - beatles.ru
Why Alto Neuroscience Inc. stock attracts strong analyst attentionFree Consultation - Newser
How Alto Neuroscience Inc. stock performs during market volatilityFree Stock Market Trend Analysis - Newser
Alto Neuroscience reprices employee stock options to $2.35 per share By Investing.com - Investing.com South Africa
Alto Neuroscience reprices employee stock options to $2.35 per share - Investing.com
Alto Neuroscience to advance depression drug after promising study By Investing.com - Investing.com South Africa
Alto Neuroscience (NYSE:ANRO) Receives Buy Rating from HC Wainwright - Defense World
Alto Neuroscience Identifies Biomarker in Phase 2 Trial for Major Depressive Disorder Patients - MarketScreener
Alto Neuroscience identifies biomarker, reports ALTO-203 pharmacodynamic results - TipRanks
Bank of America Corp DE Buys 22,007 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience : Corporate Presentation - marketscreener.com
Two Sigma Investments LP Has $130,000 Holdings in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
H.C. Wainwright Affirms Buy Rating on Alto Neuroscience (ANRO), Sets $10 PT - MSN
Jane Street Group LLC Increases Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Wellington Management Group LLP Boosts Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $15.40 Consensus Target Price from Analysts - Defense World
Nuveen Asset Management LLC Reduces Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
H.C. Wainwright maintains buy rating on Alto Neuroscience stock By Investing.com - Investing.com Canada
Alto Neuroscience acquires novel TRD treatment candidate By Investing.com - Investing.com South Africa
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal - Yahoo
Alto Neuroscience, Inc. acquired Novel Dopamine Agonist Combination Product Candidate from Chase Pharmaceuticals Corporation, Inc. - MarketScreener
Strategic Acquisition and Promising Clinical Developments Drive Buy Rating for Alto Neuroscience, Inc. - TipRanks
Alto Neuroscience Acquires Assets from Chase Therapeutics - TipRanks
Alto Neuroscience acquires dopamine agonist combination candidate - TipRanks
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway - Yahoo Finance
BNP Paribas Financial Markets Has $180,000 Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience reports progress in depression drug trials By Investing.com - Investing.com South Africa
Alto Neuroscience, Inc. Presents Data At the 2025 American Society of Clinical Psychopharmacology Annual Meeting - marketscreener.com
Alto Neuroscience reports progress in depression drug trials - Investing.com India
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder - Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
Northern Trust Corp Acquires 390,190 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
HC Wainwright Issues Pessimistic Outlook for ANRO Earnings - Defense World
Q2 Earnings Forecast for Alto Neuroscience Issued By Wedbush - Defense World
Alto Neuroscience, Inc.: Promising Clinical Trials and Strong Financial Position Justify Buy Rating - TipRanks
Equities Analysts Set Expectations for ANRO Q1 Earnings - Defense World
Wedbush Reiterates Neutral Rating for Alto Neuroscience (NYSE:ANRO) - Defense World
Alto Neuroscience Advances Precision Psychiatry Pipeline - TipRanks
Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business Highlights - marketscreener.com
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Barclays PLC - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $15.40 Average Target Price from Brokerages - Defense World
Stifel Financial Corp Takes $544,000 Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Tuesday - Defense World
0.86%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):